Dupixent: Positive Data for Children With Eosinophilic Esophagitis

Sanofi-Aventis announces the publication of phase III results for Dupixent (dupilumab) in the New England Journal of Medicine. Study finds significant improvements for children 12 months to 11 years old with eosinophilic esophagitis.

Children treated with Dupixent showed histological remission at week 16, maintained for one year. Dupixent is now approved in the United States for this indication, and authorization is pending in Europe.

Eosinophilic esophagitis, a chronic inflammatory disease, can seriously affect children's eating and growth. Dupixent showed effectiveness on several key disease indicators, compared to placebo.

Side effects were comparable to profiles seen in adults, including nausea and pain at the injection site. Dupixent is administered every two weeks depending on the child's weight.